Higher Medicaid Rebates For Expedited Approvals Offer Modest Savings But Target Growing Concern
Executive Summary
As MACPAC moves toward formal recommendations, a CBO analysis finds that differential Medicaid rebates for drugs approved through the accelerated pathway could save the federal government up to $1bn over five years.
You may also be interested in...
Medicaid Adoption Of Medicare CED Restrictions For Alzheimer’s Drugs Weighed By MACPAC
Medicaid advisory panel members suggest states should have the same flexibility as Medicare to adopt coverage with evidence development requirements for drugs with limited supporting evidence.
MACPAC ‘Undeterred’ By Lukewarm Reception Of Accelerated Drug Approval Recommendation
Executive director Schwartz suggests Congress may turn its attention to the advisory commission’s proposal to revise Medicaid coverage for drugs approved under the accelerated approval pathway in the next year or two.
Alzheimer’s Drugs Alternative Payment Models Should Get CMS Support – Duke Margolis
Some US Medicare Advantage plans are exploring alternatives to Medicare’s average sales price plus 6% payment formula for Biogen/Eisai's Aduhelm. Other MA plan sponsors urge the Medicare agency not to allow coverage for Aduhelm and similar drugs without an evidence development requirement.